ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Low Infiltration of CD8+PD-L1+T Cells and M2 Macrophages Predicts Improved Clinical Outcomes After Immune Checkpoint Inhibitor Therapy in Non-Small Cell Lung Carcinoma

Li, Liuning; Lu, Guojie; Liu, Yang; Gong, Longlong; Zheng, Xue; Zheng, Hongbo; Gu, Weiguang*; Yang, Lin广东省人民医院; 广州中医药大学; 南方医科大学; 1
Frontiers in Oncology2021-6-4DOI: 10.3389/fonc.2021.658690
12被引9阅读
引用收藏
分享

摘要

Background @@@ Many clinical studies have shown that patients with non-small cell lung carcinoma (NSCLC) can benefit from immune checkpoint inhibitor (ICI) therapy; however, PD-L1 and tumor mutation burden (TMB), which are recommended by the NCCN guidelines, are still insufficient in predicting the response to and prognosis of immunotherapy. Given the widespread use of ICIs, it is important to find biomarkers that can predict immunotherapy outcomes in NSCLC patients, and the exploration of additional effective biomarkers for ICI therapy is urgently needed. @@@ Methods @@@ A total of 33 stage II-IV NSCLC patients were included in this study. We analyzed immune markers in biopsy and surgical tissue resected from these patients before treatment with ICIs. We examined the infiltration of immune cells and expression of PD-L1 in immune cells using fluorescent multiplex immunohistochemistry (mIHC) stained with CD8/CD68/CD163/PD-L1 antibodies. @@@ Results @@@ In this cohort, we observed that the levels of CD8+ T cells, CD8+PD-L1+ T cells, and CD68+CD163+ M2 macrophages in the total region were independent prognostic factors for progression-free survival (PFS) in NSCLC patients treated with ICIs (HR=0.04, P=0.013; HR=17.70, P=0.026; and HR=17.88, P=0.011, respectively). High infiltration of CD8+ T cells and low infiltration of CD8+PD-L1+ T cells throughout the region were correlated with prolonged PFS (P=0.016 and P=0.02, respectively). No statistically significant difference was observed for CD68+CD163+ M2 macrophages. The joint parameters CD8+ high/CD8+PD-L1+ low, CD8+ high/CD68+CD163+ low and CD8+PD-L1+ low/CD68+CD163+ low predicted better PFS than other joint parameters (P<0.01, P<0.01, and P<0.001, respectively), and they also demonstrated stronger stratification than single biomarkers. The response rate of patients with high infiltration of CD8+ T cells was significantly higher than that of those with low infiltration (P<0.01), and the joint parameters CD8+/CD8+PD-L1+ and CD8+/CD68+CD163+ also demonstrated stronger stratification than single biomarkers. @@@ Conclusions @@@ This retrospective study identified the predictive value of CD8+PD-L1+ T cells, CD8+ T cells, and CD68+CD163+ M2 macrophages in NSCLC patients who received ICIs. Interestingly, our results indicate that the evaluation of joint parameters has certain significance in guiding ICI treatment in NSCLC patients.

学科与关键词

关键词
immune checkpoint inhibitor therapynon-small cell lung carcinomaT cellsmacrophagesbiomarker
相关
加载中…

文献加载失败,请重试

重试

发表信息

论文状态
公开发表
期刊
Frontiers in Oncology
发表日期
2021-06-04
卷期
第 11 卷
页码
658690
DOI
10.3389/fonc.2021.658690
期刊收录
NSL
期刊等级
3区
成果收录
SCIE

作者

  • L

    Li, Liuning (第一作者)

    2 · guangdong prov hosp · guangzhou univ chinese med

  • L

    Lu, Guojie

    1 · guangzhou panyu cent hosp

查看全部 8 位作者收起作者
  • L

    Liu, Yang

  • G

    Gong, Longlong

  • Z

    Zheng, Xue

  • Z

    Zheng, Hongbo

  • G

    Gu, Weiguang (通讯)

    2 · southern med univ

  • Y

    Yang, Lin

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417